Evidence map›Paper›PMID 36909180›Full record

ArticleFrontiers in pharmacology2023

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.

Shen Lin, Yaping Huang, Liangliang Dong, Meiyue Li, Yahong Wang, Dian Gu, Wei Wu, Dongni Nian, Shaohong Luo, Xiaoting Huang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shen LinDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yaping HuangDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Liangliang DongInstitute for Health and Aging, University of California, San Francisco, San Francisco, CA, United States.
Meiyue LiDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yahong WangDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Dian GuInstitute for Health and Aging, University of California, San Francisco, San Francisco, CA, United States.
Wei WuDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Dongni NianDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Shaohong LuoDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xiaoting HuangDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xiongwei XuDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xiuhua WengDepartment of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ASCO-VF frameworkcost-benefit analysisESMO-MCBS frameworkmalignant tumorsPD-1/PD-L1 inhibitors

Identifiers

PMID36909180
PMCPMC9995671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.